共 104 条
[11]
Tso WK(2010)Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 52-60
[12]
Omata M(2013)Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization J Hepatol 58 1181-1187
[13]
Lesmana LA(2011)EASL and mRECIST response are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial chemoembolization J Hepatol 55 1309-1316
[14]
Tateishi R(2012)Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 708-718
[15]
Llovet JM(1972)Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma Cancer Res 32 1941-1946
[16]
Bruix J(2000)Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels J Clin Gastroenterol 31 302-308
[17]
Miller AB(2009)Hepatocellular carcinoma (HCC) and diagnostic significance of alpha-fetoprotein (AFP) J Ayub Med Coll Abbottabad 21 72-75
[18]
Hoogstraten B(2018)Comparison of alpha-fetoprotein criteria and mRECIST for the prediction of overall survival of hepatocellular carcinoma patients after transarterial chemoembolization J Vasc Interv Radiol 29 1654-1661
[19]
Staquet M(2009)New utility of an old marker: serial alpha-fetoprotein measurement in prediting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 446-452
[20]
Therasse P(2012)Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma J Hepatol 57 101-107